Table 2.
The interaction between KLHLs and specific substrates about cancers
| KLHLs | Substrates | Degraded or not | Roles | References |
|---|---|---|---|---|
| KLHL2 | ARHGEF7 | Yes | Inhibition of ccRCC progression | [322] |
| UCK1 | Yes | Promotion of AML progression and 5-AZA resistance | [313] | |
| KLHL6 | CDK2 | Yes | Inhibition of AML progression | [305] |
| Roquin2 | Yes | Inhibition of DLBCL progression | [191] | |
| KLHL7 | p53 | Yes | Promotion of BC progression | [42] |
| KLHL9 | C/EBPβ, C/EBPδ | Yes | Inhibition of GBM progression | [289] |
| KLHL12 | DVL1 | Yes | Inhibition of HCC progression | [147] |
| KLHL14 | BCR | Yes | Inhibition of DLBCL progression | [156] |
| KLHL16 | NF-κB | Yes | Maintaining chemotherapy sensitivity of HNC | [155] |
| KLHL18 | PI3K | Yes | Inhibition of LC progression | [72] |
| KLHL19 | IKKβ | Yes | Inhibition of tumorigenesis | [154] |
| Myosin 9b | Yes | Inhibition of NSCLC progression | [256] | |
| SOX9 | Yes | Inhibition of tumorigenesis | [263] | |
| KLHL20 | ULK1 | Yes (K48) | Maintaining chemotherapy sensitivity of CML | [236] |
| PML | Yes | Promotion of PCa progression | [44] | |
| DAPK, PML | Yes | Promotion of CRC progression | [282] | |
| KLHL22 | DEPDC5 | Yes (K48) | Promotion of BC progression | [103] |
| PD-1 | Yes | Inhibition of CRC progression | [99] | |
| KLHL25 | ACLY | Yes | Maintaining lipid metabolism balance to suppress LC progression | [273] |
| KLHL37 | LATS1/2 | Yes | Promotion of radio-resistance of BC | [34] |
| KLHL38 | BECN1 | Yes | Promotion of BC and OC progression | [68] |
| PTEN | Yes | Promoting of NSCLC progression | [71] |
Abbreviations: ARHGEF7: Rho Guanine Nucleotide Exchange Factor 7; ccRCC: Clear Cell Renal Cell Carcinoma; UCK1: Uridine-Cytidine Kinase 1; AML: Acute Myeloid Leukemia; 5-AZA: 5-Azacytidine; CDK2: Cyclin-Dependent Kinase 2; DLBCL: Diffused Large B-Cell Lymphoma; BC: Breast Cancer; C/EBP: CCAAT Enhancer Binding Protein; GBM: Glioblastoma; DVL1: Dishevelled Segment Polarity Protein 1; HCC: Hepatocellular Carcinoma; BCR: B Cell Receptor; NF-κB: Nuclear Factor Kappa-B; HNC: Head and Neck Cancer; PI3K: Phosphatidylinositol 3-Kinase; LC: Lung Cancer; IKKβ: IkB Kinase β; NSCLC: Non-Small Cell Lung Cancer; SOX9: Sex-Determining Region Y (SRY)-Box Transcription Factor 9; ULK1: UNC-51-Like Kinase 1; CML: Chronic Myelogenous Leukemia; PML: Promyelocytic Leukemia Protein; PCa: Prostate Cancer; DAPK: Death Associated Protein Kinase; CRC: Colorectal Cancer; DEPDC5: Dishevelled, Egl-10 and Pleckstrin Domain-Containing 5; PD-1: Programmed Death-1; ACLY: ATP-Citrate Lyase; LATS1/2: Large Tumor Suppressor Kinase 1/2; BECN1: Beclin1; OC: Ovarian Cancer; PTEN: Phosphatase and Tensin Homolog.